Are You a Momentum Investor This 1 Stock Could Be the Perfect Pick
| UTHR Stock | USD 370.12 0.37 0.1% |
Slightly above 61% of United Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding United Therapeutics suggests that many traders are alarmed. United Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in United Therapeutics. Many technical investors use United Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
United |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why you should take advantage.
Read at zacks.com
 |
United Therapeutics Fundamental Analysis
We analyze United Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of United Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of United Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
United Therapeutics is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
United Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with United Therapeutics stock to make a market-neutral strategy. Peer analysis of United Therapeutics could also be used in its relative valuation, which is a method of valuing United Therapeutics by comparing valuation metrics with similar companies.
Peers
United Therapeutics Related Equities
| APLS | Apellis Pharmaceuticals | 4.39 | ||||
| LEGN | Legend Biotech | 2.95 | ||||
| BPMC | Blueprint Medicines | 1.29 | ||||
| ALNY | Alnylam Pharmaceuticals | 0.02 | ||||
| RARE | Ultragenyx | 0.06 | ||||
| AKRO | Akero Therapeutics | 0.28 | ||||
| DAWN | Day One | 0.65 | ||||
| KNSA | Kiniksa Pharmaceuticals | 1.04 | ||||
| INCY | Incyte | 1.81 | ||||
| ASND | Ascendis Pharma | 1.89 | ||||
| LRMR | Larimar Therapeutics | 2.05 | ||||
| NUVL | Nuvalent | 2.49 | ||||
| MNKD | MannKind Corp | 2.80 | ||||
| PCVX | Vaxcyte | 2.90 | ||||
| REPL | Replimune | 3.76 | ||||
| BGNE | BeiGene | 4.30 | ||||
| VTYX | Ventyx Biosciences | 5.97 |
Additional Tools for United Stock Analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.